A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Clinical trial NCT07515469 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07515469
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HCC - Hepatocellular Carcinoma Iparomlimab and Tuvonralimab Injection Neoadjuvant Immunotherapy

Start date: 2026-05-30
Primary completion: 2028-05-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.